Highest-materiality recent filing
Bausch + Lomb appoints four new directors, reaffirms 2026 guidance after Q2 revenue of $1.394B
Q2 revenue $1.394B, up 9% reported and 8% constant currency vs Q2 2025; broad-based double-digit growth in Surgical and Pharma.
Bausch + Lomb Q2 revenue $1.394B (+9% YoY); raises FY2026 guidance
Revenue $1.394B, up 9% reported and 8% constant currency YoY; GAAP net loss $14M vs $62M loss.
Bausch + Lomb Q1 2026 revenue $1.244B (+9% YoY), raises full-year guidance
Revenue $1.244B, up 9% reported and 6% constant currency YoY; GAAP net loss narrowed to $71M from $212M.
Bausch + Lomb Q4 rev $1.405B (+10%), net loss $58M; guides FY2026 rev $5.375B-$5.475B
Q4 revenue $1.405B (+10% reported, +7% constant currency); FY revenue $5.101B (+6% reported, +5% constant currency).
Bausch + Lomb completes $2.8B term loan refinancing; margin cut up to 0.50%
Entered Fourth Amendment providing $2,802,125,000 Replacement Term Loans maturing January 15, 2031.
Bausch + Lomb targets 5-7% revenue CAGR, ~23% EBITDA margin; pipeline peak sales ~$7B
Targets 5-7% constant currency revenue CAGR 2025-2028.
Bausch + Lomb Q3 revenue $1.28B (+7% YoY); narrows FY adjusted EBITDA guidance to $870M-$910M
Revenue $1.281B, up 7% reported (6% constant currency); Vision Care +8%, Surgical +4%, Pharmaceuticals +8%.
Bausch + Lomb Q2 revenue $1.278B, GAAP loss narrows to $62M, raises FY2025 guide
Revenue $1.278B, +5% as reported (+3% constant currency); Vision Care +8%, Surgical +3%, Pharma flat.
€675M senior secured floating rate notes due Jan 15, 2031, at EURIBOR + 3.875%, priced at 99.5%.
Bausch + Lomb prices €675M senior secured notes, upsizes term loan to $2.325B
Issuers priced €675M senior secured floating rate notes due 2031 at 99.500% of principal, upsized from €600M.
Bausch + Lomb launches €600M notes offering and $2.2B term loan refinancing
Subsidiaries launch €600M senior secured floating rate notes offering.
B+L reports majority shareholder BHC enters standstill pacts with Icahn, Paulson, Kavanagh
Icahn, Paulson, and Kavanagh groups agree to resign from BHC/B+L boards if they engage in Specified Actions like proxy contests or buying >19.99% of BHC.
Bausch + Lomb Q1 net loss $212M; enVista recall cuts FY adj. EBITDA guidance by ~$65M
Revenue $1.137B (+3% reported, +5% constant currency) vs $1.099B YoY.
Bausch + Lomb Q4 revenue up 11% CC; FY GAAP loss widens; guides 2025 revenue ~$5B
Q4 revenue $1.28B, up 9% reported and 11% constant currency, with growth across all segments.
Bausch + Lomb Q3 revenue $1.196B (+19% YoY); raises FY2024 revenue guidance
GAAP net income $4M vs net loss of $84M YoY; adjusted EPS $0.13 ($0.17 ex-IPR&D).
Bausch + Lomb Q2 revenue $1.216B (+17% YoY); GAAP net loss $151M; raises FY2024 guidance
Revenue $1.216B, up 17% reported and 20% constant currency vs Q2 2023.
Bausch + Lomb Q1 revenue $1.099B (+18% YoY); raises FY constant-currency growth guidance
GAAP net loss attributable widened to $167M from $90M; adjusted EBITDA rose to $180M from $141M.
Bausch + Lomb Q4 rev $1.17B (+18% YoY); guides FY 2024 rev $4.6-4.7B
Q4 2023 revenue $1.173B (+18% YoY); full-year revenue $4.146B (+10% YoY).
Bausch+Lomb completes $1.75B XIIDRA acquisition; issues $1.9B in debt at 8.375%
Acquisition closed Sep 29, 2023; upfront cash $1.75B, potential milestones up to $750M.
Bausch + Lomb discloses separation agreement terms for departing President Joseph Gordon
Cash severance of $2,203,200 (2x base salary plus target bonus).
Bausch + Lomb Q3 revenue $1.007B, raises full-year 2023 revenue and EBITDA guidance
Q3 revenue $1.007B (+7% YoY, +8% constant currency); GAAP net loss of $84M vs $18M loss prior year.
Acquired XIIDRA, libvatrep (Phase 2b), and AcuStream tech from Novartis for up to $2.5B ($1.75B upfront + $750M milestones).
Bausch + Lomb prices $1.4B 8.375% senior secured notes due 2028 for XIIDRA acquisition financing
Priced $1.4B aggregate principal of 8.375% senior secured notes due 2028 at par; closing expected Sept 29, 2023.
Bausch + Lomb launches $1.4B notes offering and $500M term loans to finance XIIDRA acquisition
$1.4B senior secured notes due 2028 offered via Bausch + Lomb Escrow Corp.; $500M term B loans also planned.
Acquisition of XIIDRA (lifitegrast) and certain ophthalmology assets from Novartis for $1.75B upfront and up to $750M milestone payments.
Purchase price of $1.75B in cash at closing, plus up to $750M in milestone payments tied to sales and pipeline achievements.
Bausch + Lomb agrees to acquire XIIDRA from Novartis for up to $2.5B
Upfront cash $1.75B plus up to $750M in milestones; total consideration up to $2.5B.
Bausch + Lomb reshapes exec team; Gordon becomes advisor, business unit heads elevated
Joseph F. Gordon transitions from President, Global Consumer, Surgical and Vision Care to strategic advisor to CEO Brent Saunders, effective June 1, 2023.
Bausch + Lomb appoints Brent Saunders as CEO and Chair, effective March 6, 2023
Brent Saunders appointed CEO and Chair, effective March 6, 2023; Joseph Papa steps down.
Bausch + Lomb CEO Joseph Papa to remain until March–June 2023; severance amended
CEO Joseph C. Papa to serve through at least March 4, 2023, and no later than June 30, 2023, under amended separation agreement.
Bausch + Lomb CEO Joseph C. Papa departing; retention program approved for other NEOs
CEO Joseph C. Papa to leave; successor search ongoing.
Mr. Richard De Schutter notified Bausch + Lomb Corporation (the “Company”) of his decision to not stand for re-election as a member of the Company’s Board of Directors (the “Board”) at the upcoming 2024 annual meeting of shareholders of the Company (the “2024 Annual Meeting”).
Ms. Karen Ling was appointed as a director of the Company, each effective immediately.
On November 6, 2023, the Company entered into a separation agreement with Mr. Gordon (the “Separation Agreement”),
On August 25, 2023, the Company entered into a separation agreement with Ms. Ackermann (the “Separation Agreement”), pursuant to which Ms. Ackermann is entitled to receive the following payments and benefits in accordance with the existing terms of her previously disclosed arrangements with the Company:
Joseph F. Gordon will transition from his current role as President, Global Consumer, Surgical and Vision Care to the new role of strategic advisor to the Chairman and Chief Executive Officer of the Company, effective June 1, 2023.
On April 12, 2023, Bausch + Lomb Corporation (the “Company”) announced the upcoming departure of Christina M. Ackermann as Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals of the Company.
Andrew Stewart will be appointed as the Company’s President, Ophthalmic Pharmaceuticals
A. Robert D. Bailey will be appointed as the Company’s Executive Vice President & Chief Legal Officer
On February 15, 2023, Bausch + Lomb Corporation (the “Company”) announced the appointment of Brent Saunders as Chief Executive Officer of the Company, effective March 6, 2023 (the “Transition Date”).
Joseph C. Papa will step down from his roles as Chief Executive Officer and member of the board of directors of the Company (the “Board”).
Effective upon Mr. Saunders’ appointment as Chair of the Board on the Transition Date, Thomas W. Ross, Sr. will become the Lead Independent Director of the Board.
Mr. Papa agreed to continue serving as Chief Executive Officer until at least March 4, 2023
Max materiality 0.90 · Median 0.60 · Most common event earnings